Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion ...
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback